QualityStocks would like to highlight Cytori Therapeutics, Inc. (NASDAQ: CYTX) , developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. Scientific data suggest ADRCs improve blood flow, moderate the immune response, and keep tissue at risk of dying alive. As a result, the company believes that these cells can be applied across multiple "ischemic" conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori's proprietary technologies and products, including the Celution® system product family.
In the company’s news yesterday,
Cytori Therapeutics announced that it has expanded the Celution System CE Mark approval in Europe to include several new indications including cryptoglandular fistula. This is the most common cause of perianal infection, abnormal fecal contamination and incontinence. This new indication will facilitate the use of the Celution System for clinical cases potentially as part of independently sponsored and funded studies. In addition to this indication, Cytori has expanded its European approval for Celution to three other indications: tissue ischemia; deficiency or injury of skin, fat, muscle and fascia; and soft tissue wounds or fistulae associated with trauma, diabetes, and ischemia or radiation injury.
In a related development, Cytori reported that an investigator-sponsored clinical study in Japan using the Celution System for treatment of cryptoglandular fistulae was approved under the new Ministry of Health, Labor and Welfare Guidelines on Clinical Research Using Human Stem Cells and patient enrollment in the study is underway. Cytori’s Celution System will be able to provide these researchers easy access to adipose-derived stem and regenerative cells at the point-of-care.
The initial impact to the company from the new indications is expected to come from additional translational system and consumable sales to meet demand by international hospitals to perform cell therapy clinical studies.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
